RTTNews BiotechDoubao · 实盘不做把握 7/10不做原因:风险收益比不佳
北京时间·🕒 发布 20:33:20·⟳ 抓取 20:45:42 +12m22s·⚡ 决策 10-13 20:49:14 +3m32s·14.0 天前
Prelude Therapeutics 与礼来达成 PRT13722 临床试验供药合作，盘前冲高回落
这是典型的大药企'供药+试验合作'协议：礼来只出药、不出钱，Prelude 无首付款/里程碑/许可收入，核心资产 PRT13722 尚处 Phase 1 启动前（仅临床前数据，2026Q4 才入组），对约 3 亿美元市值公司的基本面增量有限；盘前已演绎冲高回落（+15.8%→+2.5%），说明市场本身在 fade 该消息，追多无正期望，亦无做空催化。
📄 原文RTTNews Biotech↗ 原文
Prelude Therapeutics, Lilly Partner To Evaluate PRT13722 In Breast Cancer Trial
Prelude Therapeutics Incorporated (PRLD) has entered into a clinical trial collaboration and supply agreement with Eli…
不做 Prelude Therapeutics（PRLD.US）
供药型合作无首付款/里程碑/许可收入，PRT13722 仅 Phase 1、2026Q4 才入组，基本面增量弱；盘前已从 +15.8% 高点回落至 +2.5%，典型见光死冲高回落，且股价处 20 日下行通道，追多风险收益比不足，亦无做空级利空。
不做 Eli Lilly（LLY.US）
仅供应自家已上市药物、无费用无新增权益，事件相对礼来市值完全不具 materiality，无交易价值。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
礼来与 Prelude 的合作仅限供药、无金额条款，PRT13722 仍是 Phase 1 极早期资产；盘前脉冲式上涨已大半回吐，消息属弱验证性利好，不做。
消息传播链
- 公司美东盘前发布官方新闻稿，宣布与礼来的临床试验合作与供药协议及 IND 放行，无财务条款披露市场反应:盘前 PRLD 一度冲高至 4.33 美元（+15.8%）
- RTTNews 转载并报道盘前价 3.98 美元（+6.42%）；至 08:44 ET 实时盘前已回落至约 3.83 美元（+2.5%），显示冲高乏力、买盘不持续市场反应:盘前高点 4.33→3.83，回吐大部分涨幅
关键理由
- 唯一多头逻辑是'礼来背书'的信号价值：使用礼来两款成熟药物做联合队列，间接认可临床前协同数据，但无任何资金或商业承诺
- PRT13722 的 IND 刚获 FDA 放行、Q4 才启动入组，距离任何临床数据读出尚远，短期无新催化接续
主要风险
- 盘前从 4.33 美元高点回落至 3.83 美元，高开低走形态明显，正式开盘可能继续派发
- 小盘临床期 biotech 近 20 日下跌 18.5%、处于下行轨迹，且存在后续股权融资稀释的可能（未核实现金跑道）
反向证据
- 做多前查反向 · 来源 web · 影响 weakens
本轮未取得公司现金跑道与近期融资记录的直接证据；已知其近 20 日股价 -18.5%、处下行趋势，且存在与 Incyte 的期权合作历史，小盘临床期 biotech 的再融资稀释风险未排除
检索:Prelude Therapeutics cash runway financing dilution 2026 - 做多前查反向 · 来源 futu 实时盘前行情 · 日期 2026-10-13 · 影响 invalidates
盘前高点 4.33 美元（+15.8%）后回落至 3.83 美元（+2.5%），量能有限（盘前约 1.77 万股），冲高回落说明市场不认可该消息的实质增量
检索:PRLD premarket price action October 13 2026
先例如何影响了这次决策
对本次决策的影响:先例与实时价格行为共同支持 AVOID：不设 ENTER 腿，无需 tp/sl 校准。
方向:未构建可量化先例面板：大型药企向小型 biotech 供药用于其自有 Phase 1 试验（supply-only、无资金条款）属常规合作，历史上通常只带来个位数单日脉冲且常见当日回吐；本次盘前 +15.8%→+2.5% 的实时走势本身已提供最直接的价格证据。
涨幅量级:无干净的 aligned 高相似首发先例校准幅度；不以跨市场或低相似案例硬套止盈区间。
形态:实时盘前已出现典型见光死/冲高回落形态，且标的近 20 日为下行趋势，pattern 不支持追多。
工具执行结果 · 成功 3 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 10 ms
{"result": "search_processed_events:agent query=`prelude therapeutics lilly prt13722 phase 1 ind | prelude therapeutics prt13722 lilly collaboration breast cancer | prt13722 kat6a degrader verzenio inluriyo supply agreement`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 0.0/72 小时、0 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent quer - web_search 成功 doubao_search · 2,025 ms
豆包搜索结果（原始查询:Prelude Therapeutics Lilly PRT13722 collaboration supply agreement Verzenio Inluriyo；API SearchType:web） - stock_quote 成功 stock_tools HTTP · 420 ms
{
原文全文
展开原文 · 2,513 字
Prelude Therapeutics Incorporated (PRLD) has entered into a clinical trial collaboration and supply agreement with Eli Lilly and Company (LLY) to evaluate PRT13722 in combination with Verzenio (abemaciclib) and Inluriyo (imlunestrant) in patients with HR+/HER2- breast cancer.
HR+/HER2- breast cancer is the most common subtype of breast cancer. While existing therapies have improved outcomes for many patients, disease progression remains a challenge, creating ongoing demand for new treatment approaches.
PRT13722 is an oral KAT6A selective degrader. The company believes selectively targeting KAT6A may provide a differentiated approach compared with dual KAT6A/B inhibitors and could potentially enable effective combination therapy strategies.
Under the agreement, Lilly will supply Verzenio, a CDK4/6 inhibitor, and Inluriyo, an oral estrogen receptor antagonist, for use in Prelude's Phase 1 study. The combination cohorts will evaluate PRT13722 alongside these established breast cancer therapies.
The U.S. FDA recently cleared Prelude's Investigational New Drug (IND) Application for PRT13722, allowing the company to proceed with the Phase 1 trial. Patient enrollment is expected to begin in the fourth quarter of 2026, initially with monotherapy dose escalation before expanding into combination cohorts.
The collaboration is supported by preclinical findings presented at the 2026 American Association for Cancer Research Annual Meeting. According to Prelude, the data demonstrated that PRT13722 showed monotherapy activity and worked synergistically with both CDK4/6 inhibitors and endocrine therapies across multiple HR+/HER2-breast cancer models.
Prelude said the agreement provides an opportunity to evaluate whether combining PRT13722 with established breast cancer treatments can further improve outcomes for patients with HR+/HER2-disease.
PRLD has traded between $1.16 and $6.83 over the past year. The stock closed Monday's trading at $3.74, down 3.86%. In pre-market trading, the stock is at $3.98, up 6.42%.
For comments and feedback contact: editorial@rttnews.com
Business News
October 09, 2026 15:35 ET The minutes of the latest Federal Reserve policy session was the highlight this week which saw relatively less news on the economics front in the U.S. Latest trade data and survey results on the private sector also gained attention. In Europe, results of the purchasing managers’ survey were in focus, while the Reserve Bank of India policy announcement took the center stage in Asia.
HR+/HER2- breast cancer is the most common subtype of breast cancer. While existing therapies have improved outcomes for many patients, disease progression remains a challenge, creating ongoing demand for new treatment approaches.
PRT13722 is an oral KAT6A selective degrader. The company believes selectively targeting KAT6A may provide a differentiated approach compared with dual KAT6A/B inhibitors and could potentially enable effective combination therapy strategies.
Under the agreement, Lilly will supply Verzenio, a CDK4/6 inhibitor, and Inluriyo, an oral estrogen receptor antagonist, for use in Prelude's Phase 1 study. The combination cohorts will evaluate PRT13722 alongside these established breast cancer therapies.
The U.S. FDA recently cleared Prelude's Investigational New Drug (IND) Application for PRT13722, allowing the company to proceed with the Phase 1 trial. Patient enrollment is expected to begin in the fourth quarter of 2026, initially with monotherapy dose escalation before expanding into combination cohorts.
The collaboration is supported by preclinical findings presented at the 2026 American Association for Cancer Research Annual Meeting. According to Prelude, the data demonstrated that PRT13722 showed monotherapy activity and worked synergistically with both CDK4/6 inhibitors and endocrine therapies across multiple HR+/HER2-breast cancer models.
Prelude said the agreement provides an opportunity to evaluate whether combining PRT13722 with established breast cancer treatments can further improve outcomes for patients with HR+/HER2-disease.
PRLD has traded between $1.16 and $6.83 over the past year. The stock closed Monday's trading at $3.74, down 3.86%. In pre-market trading, the stock is at $3.98, up 6.42%.
For comments and feedback contact: editorial@rttnews.com
Business News
October 09, 2026 15:35 ET The minutes of the latest Federal Reserve policy session was the highlight this week which saw relatively less news on the economics front in the U.S. Latest trade data and survey results on the private sector also gained attention. In Europe, results of the purchasing managers’ survey were in focus, while the Reserve Bank of India policy announcement took the center stage in Asia.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
b846310ac7· 2026-10-13 20:49 · doubao / doubao-seed-evolving-latest-version · 策略包2226518bfdee当前